KURA News and Press, Kura Oncology Inc. From 05/06/21

Kura Oncology (KURA): Q1 GAAP EPS of -$0.46 misses by $0.04. $603.9 million in cash, cash equivalents and investments provide runway into 2024.Press Release For further details see: Kura Oncology EPS misses by $0.04

– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion cohorts enriched with NPM1-mutant and KMT2A-rearranged relapsed/refr...

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial results after ...

– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012...

Potbelly ([[PBPB]] +15.5%) and Shake Shack ([[SHAK]] +6.0%) are two of the big gainers in the restaurant sector on more anecdotal reports of increased dine-in traffic and further loosening of restaurant capacity restrictions in locations like Nevada, New York and New Jersey. Gainers in the re...

Image source: The Motley Fool. Kura Oncology, Inc. (NASDAQ: KURA) Q4 2020 Earnings Call Feb 24, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Kura Oncology, Inc. (KURA) Q4 2020 Earnings Call Transcript

Kura Oncology, Inc. (KURA) Q4 2020 Results Earnings Conference Call February 24, 2021, 08:00 AM ET Company Participants Pete De Spain - Investor Relations Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer Stephen Dale - Chief Medical Officer Jim Basta -...

Gainers: Sypris Solutions (SYPR) +83%.9F (JFU) +39%.Owens & Minor (OMI) +38%.Sunworks (SUNW) +34%.R. R. Donnelley & Sons (RRD) +30%.Fisker (FSR) +28%.PubMatic (PUBM) +27%.dMY Technology (DMYI) +26%.Timber Pharmaceuticals (TMBR) +25%.Cancer Genetics (CGIX) +25%.Losers: C...

Kura Oncology (KURA) has added ~14.1% in the premarket after announcing that it has received the breakthrough therapy designation from the FDA for tipifarnib in the treatment of recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (“HNSCC”...

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to inc...